UNSPSC 51263151: Bisoprolol fumarate

This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C18H31NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UR59KN573L, chemically known as 2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)- but more generally known as bisoprolol fumarate, which bears US NIH Compound Identifier 2405. European Medicines Agency schedules Bisoprolol fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00832MIG.

UNSPSC 51263151 Bisoprolol fumarate is a Commodity code for a specific beta-blocker pharmaceutical, but the recent state and local opportunities tagged under it show no activity directly matching this drug product. Instead, the two posted solicitations involve naloxone procurement and exploratory inquiry into direct-to-manufacturer prescription programs — neither of which is bisoprolol fumarate or a close therapeutic analog. The code appears to show minimal or misclassified recent activity in state and local procurement channels.

The two opportunities on record originate from a county health department and a state health agency. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023 — a date inconsistent with the June 2026 posting. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs for its Therapeutic Pharmacy Initiative, framed as exploratory market intelligence rather than a committed procurement with budget or timeline parameters. No recent opportunities target bisoprolol fumarate specifically, and the issuing bodies and geographic spread reflect only these two misaligned records. This code warrants close monitoring for evidence of either correctly classified bisoprolol procurement or clarification of why disparate products are tagged to it in state and local systems.